Financial Conflict of Interest Policy

Policy Date June 6, 2023
Introduction:

The National Institute of Health (and Public Health Service) require that companies or organizations receiving funding must establish a policy that imposes restrictions and/or procedural requirements related to financial and organization conflicts of interest. To that end, EVOQ has established and adopts the policy below which describes the requirements and procedures related to NIH requirements. EVOQ also shall ensure that this policy is maintained, kept up-to-date and enforced. It shall be available on EVOQ’s public website.

Purpose:

The purpose of this policy is to promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct, or reporting of funded research, grants or cooperative agreements will be free from bias resulting from an Investigator’s financial conflicts of interest (and/or of the Investigator’s spouse and/or dependent children). This policy complies with the following federal regulations:

- Title 42 Code of Federal Regulations (CFR), Part 50, Subpart F, Responsibility of Applicants for Promoting Objectivity in Research for Which Public Health Service Funding is Sought.

Scope:

This policy applies to Investigators participating in, or planning to participate in the design, conduct, reporting or proposing research funded by Public Health Service (PHS) or National Institute of Health (NIH).

If a research project involves subcontractors, subgrantees, or sub-awardees (collectively subrecipients), the subrecipient must provide written assurance that it has a financial conflict of interest in research policy in effect and compliant with all applicable federal regulations. Should PHS or NIH funds be subcontracted by EVOQ to a subrecipient without a conflict of interest in research policy, a written agreement must state that this policy shall apply to the subrecipient.

Definitions:

Financial Interest means anything of monetary value or potential monetary value, regardless of whether or not the value is readily ascertainable.
Investigator means the principal Investigator (PI) and any other person, regardless of title or position, who is responsible for the purpose, design, conduct, or reporting of a project funded by NIH/PHS or proposed for funding by NIH/PHS. Note: an Investigator may be an EVOQ employee, student/intern, consultant, subcontractor, or subrecipient, whether or not he/she receives income directly from EVOQ.

Financial COI means a situation in which an Investigator or the Investigator’s spouse and/or dependent children has a significant financial interest or financial relationship that could directly or significantly affect the design, conduct, reporting or funding of a project.

Significant Financial Interest (SFI) means

1. A financial interest consisting of one or more of the following interests of the Investigator (and/or of the Investigator’s spouse and/or dependent children) that reasonably appears to be related to the Investigator’s responsibilities:

   a. With regard to any publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of the disclosure, when aggregated, exceeds $5,000. For purposes of this definition, remuneration includes salary and any payment for services not otherwise identified as salary (e.g., consulting fees, honoraria, paid authorship). Equity interests include any stock, stock option, or other ownership interest, as determined through reference to public prices or other reasonable measures of fair market value.

   b. Regarding any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the Investigator (and/or the Investigator’s spouse and/or dependent children) holds any equity interest (e.g., stock, stock option, or other ownership interest); or

   c. Intellectual property rights and interests (e.g., patents, copyrights), upon receipt of income related to such rights and interests.

2. For PHS-funded Investigators, any reimbursed or sponsored travel related to an Investigator’s responsibilities, including that which is paid on behalf of the investigator so that the exact monetary value may not be readily available.

3. The term significant financial interest does not include the following types of financial interests:
a. Salary or consulting fees paid by EVOQ to the Investigator if the Investigator is currently employed or otherwise appointed by EVOQ.

However, the Investigators are required to report SFIs (foreign and domestic) from the following if the income derived from any exceeds $5,000.

b. Income from seminars, lectures, or teaching engagements sponsored by a federal, state or local agency, an institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an institution of higher education.

c. Income from service on advisory committees or review panels for a federal, state, or local government agency, an institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an institution of higher education.

d. Travel by a PHS-funded Investigator that is reimbursed or sponsored by a federal, state, or local government agency, an institution of higher education, an academic teaching hospital, a medical center, or a research institute that is affiliated with an institution of higher education.

Policy

Each year any investigator who conducts research on any EVOQ project must disclose via the electronic system all significant financial interests (SFIs) that are relevant to an investigator’s research responsibilities or within 30 days after he/she becomes aware of new SFI or after a financial conflict of interest has been eliminated.

Investigators are required to complete the annual disclosure form even if they have no financial interest to report. Transactional disclosure by the PI is also required at the time a research proposal is submitted to EVOQ’s Management Committee in order to ensure compliance with Federal disclosure and management requirements.

Procedure

Investigator Responsibilities

Investigators are responsible for:

- Disclosing all significant financial interests
- Providing updates to disclosed information as needed
If acting as the PI/PD, providing a list of individuals who meet the definition of “investigator” within the required disclosure timeline
- Completing all required training and education
- Completing the annual disclosure form even if they have no financial interests to report.

Financial Conflicts of Interest (FCOI)

A financial conflict of interest (FCOI) means a significant financial interest that could directly and significantly affect the design, conduct or reporting of research. Examples include, but are not limited to, the following:

Investigator (and/or an Investigator's spouse and/or dependent children) entering into a paid consultancy with an outside entity that has an interest in the investigator's research;
Investigator (and/or an investigator's spouse and/or dependent children) receiving royalties or non-royalty payments related to ongoing research; Investigator (and/or an investigator's spouse and/or dependent children) having an equity interest (e.g., stocks, stock options, warrants) related to ongoing research;

This policy addresses individual financial conflicts of interest; however, EVOQ may also have conflicts of interest in research whenever the financial interests of EVOQ, or of an EVOQ official acting within his or her authority on behalf of EVOQ, might affect - or reasonably appear to affect - EVOQ processes for the conduct, review, or oversight of research. If conflicts of interest are identified via the process described below, they will normally be addressed in a manner that is consistent with this policy.

Review of FCOIs

EVOQ's FCOI administrator conducts an initial review of all disclosures. If necessary, the FCOI administrator obtains additional information from the investigator and other individuals to help determine whether the SFI disclosed is related to a proposed or existing sponsored project or program. The administrator then formally identifies cases that require further review by management.

EVOQ's Management Committee (MC) will review the collected information to determine whether a financial conflict of interest exists by considering the following:

- Impact on integrity of research data;
- Risks to rights and safety of animal and/or human research subjects;

If a financial conflict of interest is identified, EVOQ’s Management Committee (MC) will determine whether the research can be undertaken.
Management of FCOIs

For cases that require action, a plan of action will be developed by members of EVOQ’s Management Committee (MC) on a case-by-case basis. Such a plan will include some or all of the following as deemed appropriate:

- Public disclosure of significant financial interests (e.g., when presenting or publishing the research), if appropriate;
- Disclosure of significant financial interests directly to subjects involved in human research;
- Appointment of an independent monitor capable of taking measures to protect the design, conduct, and reporting of research;
- Modification of research plan;
- Change of personnel or personnel responsibilities or disqualification from participation in all or a portion of the research;
- Reduction or elimination of the financial interest (e.g., sale of an equity interest);
- Severance of relationships that create the actual or potential conflict of interest;
- If it proves impossible to reach an acceptable plan of action, funds will be returned to the sponsor.

A draft of the plan of action will be provided to the Investigator for review and comment before it is finalized. The Investigator and their immediate supervisor must sign the approved plan to acknowledge their agreement to comply.

If the EVOQ identifies an SFI that was not disclosed or reviewed in a timely manner it will initiate the review process and an interim plan of action will be implemented when necessary.

Monitoring

Investigator compliance with plans of action will be monitored by EVOQ’s Management Committee (MC). The frequency of monitoring will be dictated by sponsor/agency requirements and action plan provisions.

Research Involving Humans

Special consideration and scrutiny must be given to protect human subjects in research. Investigators with an identified financial conflict of interest or a significant financial interest that could directly and significantly affect the design, conduct, or reporting of the research shall not ordinarily participate in any research involving human subjects. This presumption against the participation in human subjects’ research by financially interested individuals may be rebutted by compelling circumstances. Compelling justification may include factors such as unique investigator expertise, unique resources, unique access to particular patient populations, nature of the science, level of risk to
human subjects and the degree to which the financial conflict of interest and the research are related.

The compelling justification and the degree of risk to human subjects must be presented and reviewed by the Management Committee (MC). If compelling circumstances justify a waiver of this policy, the research will be subject to the development and implementation of an action plan to ensure the safety of human subjects and the integrity of the research. The MC must review the research with consideration given to the requirements of the action plan. The MC may require additional safeguards to be implemented but may not determine less stringent financial conflict of interest management requirements.

**Confidentiality**

Financial and other information disclosed in compliance with this policy will be kept confidential and disclosed only on a need-to-know basis as required to perform appropriate review and evaluation required by the policy, except in the case of required public accessibility of identified financial conflicts of interest.

**Enforcement**

Failure on the part of an Investigator to comply with this policy will result in disciplinary action and/or sanctions which may include formal reprimand, non-renewal/termination of appointment or affiliation, additional training requirements, additional supervision, closing existing research or denying future research by the Investigator, and/or any other enforcement action mandated by the applicable funding agency or EVOQ.

**Policy Revision**

EVOQ may modify this policy to conform to organizational changes and circumstances including revisions to federal or state law or regulations. The MC will have 30 business days to review and comment on any proposed revisions.

The Executive Committee of EVOQ’s Board of Directors is responsible for granting final approval for these policy revisions. It will review all proposed revisions, in collaboration with management, and will consider the committee’s feedback during the review process. When necessary, procedures will be developed or modified to implement this policy.

**Additional Requirements**

The following additional requirements also apply to all research funded by the PHS of the U.S. Department of Health and Human Services and any PHS Awarding Component including the NIH.
Reporting

EVOQ will provide to the PHS Awarding Component a FCOI report as outlined in the regulations:

Initial Report: Prior to expenditure of any funds under the NIH-funded research project, the EVOQ will provide a FCOI report regarding any SFI found to be a FCOI. EVOQ will also provide a FCOI report within 60 calendar days from the date of a new SFI disclosure determined to be a FCOI, a new Investigator with an identified FCOI becomes engaged in the project or when the EVOQ identifies a FCOI not previously disclosed. This report will include the following information:

- Grant/Contract Number
- PD/PI
- Name of Investigator with FCOI
- Nature of the FCOI (e.g., equity, consulting fees, travel reimbursement or honoraria)
- Value of the financial interest or a statement that the interest is one whose value cannot be readily determined through reference to public prices or other reasonable measures of fair market value
- Description of how FCOI relates to PHS-funded research and the basis for the determination that the financial interest conflicts with such research
- Key elements of the FCOI action plan

Annual updates to this report will be submitted to the PHS Awarding Component for the duration of the research project. The annual report will include:

- Status of the FCOI
- Changes to the action plan
- Justification that an FCOI no longer exists

Subrecipients

For PHS-funded research that involves subcontractors, subgrantees or subawardees (collectively subrecipients) at other EVOQs, EVOQ requires a written agreement that includes terms that establish whether the FCOI policy of the awardee EVOQ or that of the subrecipient EVOQ will apply to subrecipient Investigators. This agreement will specifically address time periods to meet disclosure and/or financial conflict of interest reporting requirements.

Subrecipient EVOQs who rely on their Financial Conflict of Interest policy must report identified financial conflicts of interests to the EVOQ in sufficient time to allow the EVOQ to report the FCOI to the PHS Awarding component.
Subrecipients who do not have such a conflict of interest policy will be required to follow the EVOQ FCOI in Research policy, which shall be incorporated into any subcontract or subaward. A subrecipient’s failure to promptly comply with the EVOQ policy will be considered grounds for immediate termination by EVOQ of any applicable subcontract or subaward. The written agreement terms required by EVOQ will contain a provision that subrecipients will report to EVOQ as the pass-through entity, any identified FCOI in sufficient time to allow EVOQ to report and manage the FCOI and meet the reporting obligations described above.

Public Accessibility

EVOQ shall ensure that this FCOI policy is publicly accessible through EVOQ’s website.

Information concerning identified FCOIs concerning significant financial interest(s) held by Investigators or other senior/key personnel will be made available to requestors via an email.

Training Requirements

NIH/PHS-funded Investigators must complete FCOI training prior to engaging in research related to any NIH/PHS-funded grant or contract and at least every four years thereafter. Training must also be completed as soon as reasonably possible under the following circumstances:

- This policy changes in a manner that affects Investigator requirements
- An Investigator is new to a subrecipient and will be working on PHS-funded research
- An Investigator is found to be noncompliant with this policy or their approved action plan

Investigator Non-Compliance

If an SFI is not disclosed or reviewed in a timely manner, EVOQ will review the Investigator’s financial interest, and determine if it is related to NIH/PHS-funded research; determine whether an FCOI exists, and if so:

- Implement an action plan for ongoing research, at a minimum implement an interim action plan employing FCOI management, prospective avoidance or mitigation.
- Complete a retrospective review of Investigator’s activities and the PHS-funded research project within 120 days of a non-compliance finding to determine if bias was present in the design, conduct, or reporting of such research; and
- If bias/non-compliance is found, the EVOQ will promptly inform the PHS Awarding Component by submitting a mitigation report
If the retrospective review finds that the Investigator knew, or should have known about the FCOI related to his/her responsibilities, but failed to disclose in compliance with this policy, the costs associated with the retrospective review and mitigation report may be pulled from the Investigator’s compensations or, if a subrecipient, its Indirect Cost Allocation portion. If the Department of Health and Human Services determines that a PHS-funded clinical research project whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment has been designed, conducted, or reported by an Investigator with a conflicting interest that was not managed or reported to EVOQ, the Investigator must disclose the FCOI in each public presentation of the results of the research and must request an addendum to previously published presentations.

**NIH Reporting Requirements**

If EVOQ is unable to satisfactorily manage a conflict of interest involving NIH funding, it will appropriately notify NIH’s Office of the General Counsel.

**Responsibilities and Authorities:**

Investigators participating in, or planning to participate in the design, conduct, or reporting of research including Public Health Service (PHS) or National Institute of Health (NIH) funded research at EVOQ have the authority and responsibility for the activities in this policy.

**Records**

EVOQ will maintain all records related to the implementation of this policy for at least three years after:

- the date of creation;
- the date of termination or completion of a research award or contract;
- the submission of the final expenditures report; or
- the date of final resolution of any investigation, audit, or similar action involving the records.